Pyxis Oncology (PYXS) Operating Leases (2020 - 2025)

Pyxis Oncology (PYXS) has 5 years of Operating Leases data on file, last reported at $17.0 million in Q4 2025.

• On a quarterly basis, Operating Leases fell 9.07% year-over-year to $17.0 million in Q4 2025; TTM through Dec 2025 was $17.0 million, a 9.07% decrease from a year earlier, with the FY2025 full-year figure at $17.0 million, down 9.07% from the prior year.
• Operating Leases for Q4 2025 stood at $17.0 million, down from $17.4 million in the prior quarter.
• Over the last five years, Operating Leases for PYXS reached as high as $20.7 million in Q2 2023 and fell as low as $15.7 million in Q2 2022.
• Historically, Operating Leases has averaged $18.5 million across 4 years, with a median of $18.9 million in 2022.
• Across the five-year window, Operating Leases jumped 32.2% in 2023 and declined 9.07% in 2025, its largest moves.
• Year by year, Operating Leases stood at $18.9 million in 2022, then advanced by 6.23% to $20.1 million in 2023, then fell by 7.21% to $18.6 million in 2024, then retreated by 9.07% to $17.0 million in 2025.
• Per Business Quant data, the three most recent Operating Leases figures were $17.0 million in Q4 2025, $17.4 million in Q3 2025, and $17.8 million in Q2 2025.